HLS Therapeutics Inc T.HLS

Alternate Symbol(s): HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

TSX:HLS - Post by User

HLS Therapeutics Inc

Bullboard Posts

Post by StompinTomon Apr 27, 2015 1:18pm

183 Views

Post# 23667970

Info circular

So according to the inforamtion circular, only the CFO in on a full employment contract and even at that is for 3 months to June 26. Everyone else is a consultant on anything from month to month or quarterly. The CEO and BD guy contracts are tied to the GM litigation.

Q1 will be interesting from a net asset value as the cash value of severances/receivables/inventory etc. should largely be harvested.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide